Lexicon Hires Former Eisai President and CEO
Lexicon Pharmaceuticals hired Lonnel Coats as President and Chief Executive Officer. Coats brings 18 years of service at Eisai where he most recently held the positions of President and Chief Operating Officer from 2004 to 2010 and then served as President and CEO for the last four years. Coats oversaw the commercialization of products in the oncology, neurology, GI, epilepsy and metabolic areas, and oversaw the expansion of Eisai’s business across the Americas and market approvals in Canada for three drug products. “We sought a seasoned and dynamic executive with an exceptional understanding of bringing drugs to the market,” said Raymond Debbane, Chairman of the Board. “Lonnel brings an ideal blend of operational intelligence, business development acumen and proven leadership.”
Seasoned Strategist in Life Sciences Joins Consulting Firm
Partha Anbil recently joined Strategy& (formerly Booz & Company), part of the PricewaterhouseCoopers (PwC) network as Executive Advisor, Global Health & Life Sciences Practice. Prior to his appointment, Anbil served as Associate Partner, Strategy & Transformation Practice, Healthcare & Life Sciences Industry at IBM Global Business Services, where he led a go-to-market strategy, sales support and also directed a global team to deliver solutions to clients on time and on budget. Anbil brings more than two decades of management consulting experience in the health and life sciences industry with leadership positions held in Wolters Kluwer Pharma Solutions, IMS Health, KPMG and PricewaterhouseCoopers. He currently serves on the Board of Directors of CMR Institute, an institution dedicated to offering expert healthcare training programs, as lead faculty and advisory board member for the Institute of Pharmaceutical Management and serves on the editorial advisory board for PM360 Magazine.
The clinical stage diagnostics company hired Sean Nolan as Chief Technology Officer. Nolan brings 13 years experience at Microsoft in healthcare software architecture, most recently serving as General Manager and Distinguished Engineer for HealthVault and the Health Solutions Group. He will oversee Adaptive’s software development and architecture, IT and automation.
A clinical stage pharmaceutical company focused on discovering, developing and commercializing treatments for glaucoma hired Michael McCleerey to the newly established position of Vice President, Marketing. He will be responsible for preparing for the commercialization of the company’s lead product candidates. He has more than 25 years experience in the pharma industry and has held positions at ISTA Pharma and Allergan.
Upon completion of the tax-free distribution of the company’s biopharmaceuticals business, Robert J. Hombach will be named Chief Financial Officer of the newly independent company and will assume additional operational responsibilities. Hombach will report to Ludwig N. Hantson, PhD, the company’s new CEO.
Appointed Malini Moorthy as Head of the U.S. Litigation Department. She joins the company from Pfizer where she’s held leadership roles for the past 10 years. She most recently served as VP and Assistant General Counsel and Head of Civil Litigation.
A clinical stage biopharmaceutical company focused on diabetes treatments, promoted Mark Robbins, PhD, JD to Executive Vice President. He served as Vice President, Clinical and Regulatory Affairs since joining the company in December 2012 and will continue to oversee the company’s clinical development programs.
A company focused on the discovery and development of novel cancer therapies, hired Richard Murray, PhD as CEO. Murray brings more than 20 years experience in biologics R&D for both start-up biotechnology and large pharmaceutical companies. He joins the company from Merck, where he most recently served as SVP, Biologics and Vaccines Research, and was a member of the Merck Research Labs leadership team.
Hired Ritesh Patel as Executive Vice President, Chief Digital Officer. Patel will be responsible for leading the agency’s NJ- and NY-based digital groups overseeing and driving the expansion of the teams’ offerings and client base, and will collaborate with chief creative officers to manage the agency’s technology groups to ensure high-quality digital experience and output.
The biotechnology company appointed Eugen Leo, MD, PhD, as Head of Clinical Development. Leo has more than 15 years of experience in Phase I-III clinical development of targeted and first-in-class molecules, as well as extensive translational research experience. In his new position he will play a crucial role for driving Oxford’s pipeline of antibody-drug conjugates (ADCs) into clinical development.
Elected James C. Smith to its Board of Directors, and was appointed to the Corporate Governance and Science and Technology Committees of the board. He currently serves as the President and CEO of Thomson Reuters and also serves on its Board of Directors.
The Novato, CA-based pharmaceutical company promoted Julie Anne Smith to President and CEO-designate. Smith previously held the position of Executive Vice President, Strategy and Chief Operating Officer, where she led the development of commercial strategy for Raptor’s first commercial product.
The clinical stage biotechnology company focused on cancer therapeutics, appointed Ronald A. Martell as CEO. Over the course of his 25-year career, Martell has successfully led biotech companies. He recently served as President and CEO of NeurogesX, and was previously CEO of Poniard Pharmaceuticals.
Strand Life Sciences
The company that innovates personalized medicine products using genomics technology hired Scott Storrer as President of North America. He will oversee strategy, expansion and operation of the company. Storrer joins Strand from Genomind, a personalized medicine company that provides diagnostic tests for behavioral health, where he served as President and CEO.